| Literature DB >> 15474868 |
Verena Niederberger1, Rudolf Valenta.
Abstract
For more than 90 years, allergen-specific immunotherapy, the only causative allergy treatment, has remained basically unchanged. The development of molecular biology techniques has led to the preparation of individual recombinant allergens from the most important allergen sources. Recombinant allergens can be used to determine the individual sensitization profile of allergic patients and have allowed the development of novel therapeutic tools. This article summarizes data on genetically modified recombinant allergen derivatives with reduced allergenic activity, which may be used to improve the safety and efficacy of specific immunotherapy.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15474868 DOI: 10.1016/j.iac.2004.06.009
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN: 0889-8561 Impact factor: 3.479